SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $532,102,416 |
| Positions | 39 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $55,168,324 | 1,675,830 |
| JOHNSON & JOHNSON | JNJ | COM | $35,288,116 | 138,946 |
| GILEAD SCIENCES INC | GILD | COM | $34,024,499 | 269,309 |
| BRIDGEBIO PHARMA INC | BBIO | COM | $33,891,454 | 455,041 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $26,575,158 | 1,215,698 |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $26,468,091 | 562,672 |
| BRISTOL-MYERS SQUIBB CO | BMY | COM | $23,794,813 | 412,961 |
| PARABILIS MEDICINES INC | PBLS | COM | $22,554,057 | 824,043 |
| NATERA INC | NTRA | COM | $22,308,032 | 82,181 |
| INCYTE CORP | INCY | COM | $21,722,837 | 191,627 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.